Ben Lamm’s $3.7 Billion Net Worth in 2025: The Entrepreneur Behind Colossal Biosciences and De-Extinction Innovations
As of 2025, Ben Lamm, an American serial entrepreneur, has amassed a net worth of $3.7 billion. He is best known for co-founding Colossal Biosciences, a groundbreaking biotechnology company focused on de-extinction—the process of reviving extinct species. Lamm’s partnership with renowned geneticist George Church has positioned him at the forefront of genetic engineering and conservation efforts.
Early Entrepreneurial Ventures
Before venturing into the realm of biotechnology, Ben Lamm established himself as a dynamic entrepreneur with a series of successful tech startups. His ventures often centered around emerging technologies and innovative solutions, laying the foundation for his future endeavors in more complex scientific fields.
Founding of Colossal Biosciences
In 2021, Lamm co-founded Colossal Biosciences alongside Harvard geneticist George Church. The company’s mission is ambitious: to leverage advanced genetic engineering techniques, particularly CRISPR technology, to bring back extinct species such as the woolly mammoth, the Tasmanian tiger, and the dodo. Colossal aims to reintroduce these species into their natural habitats, thereby restoring ecological balance and promoting biodiversity.
Breakthroughs in De-Extinction
Colossal Biosciences has achieved significant milestones in the field of de-extinction. Notably, the company announced the successful birth of genetically engineered dire wolf pups—Romulus, Remus, and Khaleesi—in October 2024. This achievement marked the world’s first successful de-extinction of an animal, showcasing the practical applications of Colossal’s genetic technologies.
In addition to the dire wolf project, Colossal has made strides in other de-extinction efforts. The company has been working on creating “woolly mice” by introducing mammoth genes into mouse genomes, a step towards understanding and eventually reviving the woolly mammoth.
Financial Growth and Valuation
Colossal Biosciences’ innovative approach has attracted substantial investment. In January 2025, the company secured $200 million in Series C funding, elevating its valuation to an impressive $10.2 billion. This influx of capital has propelled Lamm’s personal net worth to $3.7 billion, underscoring the financial viability and investor confidence in Colossal’s mission.
Ethical Considerations and Future Prospects
While Colossal’s endeavors have garnered excitement, they have also sparked ethical debates within the scientific community. Concerns revolve around the ecological implications of reintroducing extinct species and the prioritization of resources that might otherwise support existing conservation efforts. Lamm and his team address these concerns by emphasizing the potential benefits of their work, including biodiversity restoration and the development of technologies that could aid in conserving endangered species.
Conclusion
Ben Lamm’s journey from tech entrepreneur to biotech pioneer reflects a commitment to leveraging technology for transformative purposes. Through Colossal Biosciences, he is not only redefining the boundaries of genetic science but also contributing to conservation in unprecedented ways. As of 2025, with a net worth of $3.7 billion, Lamm stands as a testament to the potential of innovative entrepreneurship to drive significant scientific and ecological advancements.
